ArticleCureus2026
Clinical Significance of the Identification of an Anti-M (IgG) Alloantibody in Pregnancy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-M is usually a naturally occurring, cold-reactive immunoglobulin M (IgM) antibody and is commonly regarded as clinically insignificant. An immunoglobulin G (IgG) component, however, can cross the placenta and has rarely been associated with hemolytic disease of the fetus and newborn (HDFN), including hyporegenerative fetal or neonatal anemia. A 42-year-old woman (G4P2A2) undergoing preconception evaluation had a positive indirect antiglobulin test (IAT) with initially inconclusive antibody identification. Reference immunohematology testing identified anti-M reactivity at 4°C. After dithiothreitol (DTT) treatment, an immunoglobulin G component was confirmed at a titer of 1:2. The direct antiglobulin test (DAT) remained negative, and there was no evidence of maternal hemolysis. Her partner was M antigen positive, indicating that a future fetus could inherit the target antigen. This case shows that detailed characterization of an apparently cold-reactive anti-M antibody can materially change preconception counseling and pregnancy planning. Low titer alone should not replace consideration of antibody class, thermal amplitude, obstetric history, paternal or fetal antigen status, and coordinated follow-up by transfusion medicine and maternal-fetal medicine teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.